Belgian women’s health specialist Mithra Pharmaceuticals says the Canadian and US approvals and European endorsement received for its Estelle (estetrol/drospirenone) 15mg/3mg oral contraceptive mark a “turning point in its history,” following the firm’s previous successes with products including its Myring (etonogestrel/ethinylestradiol) generic rival to Merck & Co’s NuvaRing vaginal ring for which it expects to see further launches later this year.
Estelle was approved for the first time worldwide in Canada in early March, under the name Nextstellis, with a Canadian...
